Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
ANIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.40 - $29.12
Previous CloseN/A
Volume22.29K
Average Volume (3M)62.03K
Market Cap
$258.49M
Enterprise Value$329.94M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 01, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.64
Shares Outstanding14,645,596
10 Day Avg. Volume58,768
30 Day Avg. Volume62,027
Standard Deviation0.11
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.59
Price to Cash Flow (P/CF)13.00
P/FCF Ratio20.40
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-14.29
Forecast
1Y Price Target
$25.00Price Target Upside43.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Anika Therapeutics News
PremiumPre-Earnings
Is ANIK a Buy, Before Earnings?
PremiumCompany Announcements
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
PremiumCompany Announcements
Anika Therapeutics Focuses on Core Growth Amid Restructuring
PremiumCompany Announcements
Anika Therapeutics Refocuses on Core Technology and Growth
---
Bulls Say, Bears Say
Bulls Say
Business GrowthNew products are expected to primarily fuel the double-digit growth in the company's Joint Preservation & Restoration business.
Investment RatingAnika is maintaining an OUTPERFORM investment rating despite challenges.
Product LaunchesThe upcoming U.S. commercial launches of Cingal and Hyalofast could have a significant financial impact.
Bears Say
Financial PerformanceAdjusted EPS of -$0.25 fell massively short of expectations.
Guidance ReductionManagement significantly reduced its previous adjusted EBITDA guidance for the fiscal year, reflecting a more pessimistic outlook.
Regulatory ChallengesCingal has been stalled from a regulatory perspective due to slow-moving conversations with the FDA.
---
Ownership Overview
3.21% Insiders
14.85% Mutual Funds
39.90% Other Institutional Investors
30.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $15.40 and its highest was $29.11 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $258.49M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Anika Therapeutics’s earnings last quarter?
Currently, no data Available
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 14,645,596 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
---
Anika Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (43.76% Upside)
$25.00 (43.76% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.21%
12-Months-Change
Fundamentals
Return on Equity
-43.31%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
---
ANIK Company Deck
---
ANIK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strategic shifts focusing on HA-based products and international growth. However, significant challenges included the divestiture of underperforming assets and declining U.S. revenue. Despite these setbacks, growth in international markets and regulatory progress for key products provide a positive outlook.Read More>---
ANIK Stock 12 Month Forecast
Average Price Target
$25.00
▲(43.76% Upside)
Technical Analysis
Best Analysts Covering ANIK
1 Year
1 Year Success Rate
6/25 ratings generated profit
1 Year Average Return
-11.13%
reiterated a buy rating 4 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 24.00% of your transactions generating a profit, with an average return of -11.13% per trade.
---